The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemiaEytan M. Stein, Martin S. Tallman, Guillermo Garcia‐Manero et al.|Blood|2018Cited by 457
Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphomaChristopher Rushton, Ryan D. Morin, Kirstie L.S. Cleary et al.|Blood Advances|2020Cited by 120
The DOT1L Inhibitor EPZ-5676: Safety and Activity in Relapsed/Refractory Patients with MLL-Rearranged LeukemiaEytan M. Stein, Martin S. Tallman, Guillermo Garcia‐Manero et al.|Blood|2014Cited by 44